Lizards can regrow entire limbs. Flatworms, starfish, and sea cucumbers regrow entire bodies.
Sharks constantly replace lost teeth, often growing over 20,000 teeth throughout their lifetimes.
How can we translate these near-superpowers to humans? The answer: through the cutting-edge innovations of regenerative medicine.
Investors pumped $10 billion into regenerative medicine in 2019, with venture financing increasing 33% compared to the prior year. Over 1,000 clinical trials are underway worldwide, bringing regenerative treatments to 60,000 patients.
While Big Data and Artificial Intelligence transform how we practice medicine and invent new treatments, regenerative medicine is about replenishing, replacing, and rejuvenating our physical bodies.
In this blog, I’ll explore the three R’s of Regenerative Medicine:
- Replenish: Stem Cells - The Regenerative Engine of The Body
- Replace: Organ Regeneration and Bioprinting
- Rejuvenate: Young Blood & Parabiosis
Let’s dive in.
Replenish: Stem Cells – The Regenerative Engine of the Body
Stem cells are undifferentiated cells that can transform into specialized cells such as heart, neurons, liver, lung, skin and so on, and can also divide to produce more stem cells.
In a child or young adult, these stem cells are in large supply, acting as a built-in repair system. They are often summoned to the site of damage or inflammation to repair and restore normal function.
But as we age, our supply of stem cells begins to diminish as much as 100- to 10,000-fold in different tissues and organs. In addition, stem cells undergo genetic mutations, which reduce their quality and effectiveness at renovating and repairing your body.
Imagine your stem cells as a team of repairmen in your newly constructed mansion. When the mansion is new and the repairmen are young, they can fix everything perfectly.
But as the repairmen age and reduce in number, your mansion eventually goes into disrepair and finally crumbles.
What if you could restore and rejuvenate your stem cell population?
One option to accomplish this restoration and rejuvenation is to extract and concentrate your own autologous adult stem cells from places like your adipose (fat) tissue or bone marrow.
These stem cells, however, are fewer in number and have undergone mutations (depending on your age) from their original ‘software code.’
Many scientists and physicians now prefer an alternative source, obtaining stem cells from the placenta or umbilical cord, the leftovers of birth.
These stem cells, available in large supply and expressing the undamaged software of a newborn, can be injected into joints or administered intravenously to rejuvenate and revitalize.
Think of these stem cells as chemical factories generating vital growth factors that can help to reduce inflammation, fight autoimmune disease, increase muscle mass, repair joints, and even revitalize skin and grow hair.
Over the last decade, the number of publications per year on stem cell-related research has increased 40-fold.
The global stem cell market is estimated to reach $14.8 billion by 2022, growing at a CAGR of 14.7% for the period of 2017-2022.
Rising R&D initiatives to develop therapeutic options for chronic diseases and growing demand for regenerative treatment options are the most significant drivers of this budding industry.
Biologists led by Kohji Nishida at Osaka University in Japan have discovered a new way to nurture and grow the tissues that make up the human eyeball.
The scientists are able to grow retinas, corneas, the eye’s lens and more, using only a small sample of adult skin.
In a Stanford study, seven of 18 stroke victims who agreed to stem cell treatments showed remarkable motor function improvements.
This treatment could work for other neurodegenerative conditions such as Alzheimer’s, Parkinson’s and ALS.
Doctors from the USC Neurorestoration Center and Keck Medicine of USC injected stem cells into the damaged cervical spine of a recently paralyzed 21-year-old man.
Three months later, he showed dramatic improvement in sensation and movement of both arms.
In 2019, doctors in the U.K. cured a patient with HIV for the second time ever thanks to the efficacy of stem cells. After giving the cancer patient (who also had HIV) an allogeneic haematopoietic (e.g. blood) stem cell treatment for his Hodgkin’s lymphoma, the patient went into long-term HIV remission — 18 months and counting at the time of the study’s publication.
In 2017, Dr. Bob Hariri and I announced a new company called Celularity.
Celularity is built on 20 years of research conducted by Dr. Hariri and his team on the placenta, its cells and tissues. Decades ago, he recognized the power of the placenta, what I often describe as the 3D printer that creates an embryo. He set out to harness the power of placental cells to augment our biology, immunity and longevity.
Celularity focuses on three primary stem cell technologies:
- Biosourcing: “saving your child’s boot-disk”
- Function regeneration
- Cell therapy
You can learn more about Celularity’s transformative work here.
Replace: Organ Regeneration & 3D Printing
Every 10 minutes, someone is added to the U.S. organ transplant waiting list, totaling over 112,000 people waiting for replacement organs as of March 2020.
Countless more people in need of ‘spare parts’ never make it onto the waiting list. And on average, 20 people die each day while waiting for a transplant.
As a result, 35 percent of all U.S. deaths (~900,000 people) could be prevented or delayed with access to organ replacements.
The excessive demand for donated organs will only intensify as technologies like self-driving cars make the world safer, given that many organ donors result from auto and motorcycle accidents. Safer vehicles mean less accidents and donations.
Clearly, replacement and regenerative medicine represent a massive opportunity.
Figure: The organ transplant waiting list is growing significantly faster than the number of transplants and available donors.
Enter United Therapeutics CEO, Dr. Martine Rothblatt. A one-time aerospace entrepreneur (she was the founder of Sirius Satellite Radio), Rothblatt changed careers in the 1990s after her daughter developed a rare lung disease.
Her Moonshot today is to create an industry of replacement organs. With an initial focus on diseases of the lung, Rothblatt set out to create replacement lungs. To accomplish this goal, her company United Therapeutics has pursued a number of technologies in parallel.
3D Printing Lungs
In 2017, United teamed up with one of the world’s largest 3D printing companies, 3D Systems, to build a collagen bioprinter and is paying another company, 3Scan, to slice up lungs and create detailed maps of their interior.
This 3D Systems bioprinter now operates according to a method called stereolithography. A UV laser flickers through a shallow pool of collagen doped with photosensitive molecules. Wherever the laser lingers, the collagen cures and becomes solid.
Gradually, the object being printed is lowered and new layers are added. The printer can currently lay down collagen at a resolution of around 20 micrometers but will need to achieve resolution of a micrometer in size to make the lung functional.
Once a collagen lung scaffold has been printed, the next step is to infuse it with human cells, a process called recellularization.
The goal here is to use stem cells that grow on scaffolding and differentiate, ultimately providing the proper functionality. Early evidence indicates this approach can work.
In 2018, Harvard University experimental surgeon Harald Ott reported that he pumped billions of human cells (from umbilical cords and diced lungs) into a pig lung stripped of its own cells.
When Ott’s team reconnected it to a pig’s circulation, the resulting organ showed rudimentary function.
Figure: 3D printed structure mimicking part of a human airway.
Humanizing Pig Lungs
Another of Rothblatt’s organ manufacturing strategies is called xenotransplantation, the idea of transplanting an animal’s organs into humans who need a replacement.
Given the fact that adult pig organs are similar in size and shape to those of humans, United Therapeutics has focused on genetically engineering pigs to allow humans to use their organs. “It’s actually not rocket science,” said Rothblatt in her 2015 TED talk. “It’s editing one gene after another.”
To accomplish this goal, United Therapeutics made a series of investments in companies such as Revivicor Inc. and Synthetic Genomics Inc., and signed large funding agreements with the University of Maryland, University of Alabama, and New York-Presbyterian/Columbia University Medical Center to create xenotransplantation programs for new hearts, kidneys and lungs, respectively.
Rothblatt hopes to see human translation in three to four years.
In preparation for that day, United Therapeutics owns a 132-acre property in Research Triangle Park and built a 275,000-square-foot medical laboratory that will ultimately have the capability to annually produce up to 1,000 sets of healthy pig lungs — known as xenolungs — from genetically engineered pigs.
Lung Ex Vivo Perfusion Systems
Beyond 3D printing and genetically engineering pig lungs, Rothblatt has already begun implementing a third, near-term approach to improve the supply of lungs across the U.S.
Only about 30 percent of potential donor lungs meet transplant criteria in the first place; of those, only about 85 percent of those are usable once they arrive at the surgery center.
As a result, nearly 75 percent of possible lungs never make it to the recipient in need.
What if these lungs could be rejuvenated? This concept informs Dr. Rothblatt’s next approach.
In 2016, United Therapeutics invested $41.8 million in TransMedics Inc., an Andover, Massachusetts company that develops ex vivo perfusion systems for donor lungs, hearts and kidneys.
The XVIVO Perfusion System takes marginal-quality lungs that initially failed to meet transplantation standard-of-care criteria and perfuses and ventilates them at normothermic conditions, providing an opportunity for surgeons to reassess transplant suitability.
Rejuvenate Young Blood & Parabiosis
In HBO’s parody of the Bay Area tech community, “Silicon Valley,” one of the episodes (Season 4, Episode 5) is named “The Blood Boy.”
In this installment, tech billionaire Gavin Belson (Matt Ross) is meeting with Richard Hendricks (Thomas Middleditch) and his team, speaking about the future of the decentralized internet. A young, muscled twenty-something disrupts the meeting when he rolls in a transfusion stand and silently hooks an intravenous connection between himself and Belson.
Belson then introduces the newcomer as his “transfusion associate” and begins to explain the science of parabiosis: “Regular transfusions of the blood of a younger physically fit donor can significantly retard the aging process.”
While the sitcom is fiction, that science has merit, and the scenario portrayed in the episode is already happening today.
On the first point, research at Stanford and Harvard has demonstrated that older animals, when transfused with the blood of young animals, experience regeneration across many tissues and organs.
The opposite is also true: young animals, when transfused with the blood of older animals, experience accelerated aging.
But capitalizing on this virtual fountain of youth has been tricky.
One company, a San Francisco-based startup called Ambrosia, recently commenced one of the trials on parabiosis.
Their protocol is simple: Healthy participants aged 35 and older get a transfusion of blood plasma from donors under 25, and researchers monitor their blood over the next two years for molecular indicators of health and aging.
Ambrosia’s founder Jesse Karmazin became interested in launching a company around parabiosis after seeing impressive data from animals and studies conducted abroad in humans: In one trial after another, subjects experience a reversal of aging symptoms across every major organ system.
"The effects seem to be almost permanent," he said. "It's almost like there's a resetting of gene expression."
Infusing your own cord blood stem cells as you age may have tremendous longevity benefits.
Following an FDA press release in February 2019, Ambrosia halted its consumer-facing treatment after several months of operation.
Understandably, the FDA raised concerns about the practice of parabiosis because to date, there is a marked lack of clinical data to support the treatment’s effectiveness.
On the other end of the reputability spectrum is a startup called Elevian, spun out of Harvard University. Elevian is approaching longevity with a careful, scientifically validated strategy. (Full Disclosure: I am both an advisor to and investor in Elevian.)
CEO Mark Allen, MD, is joined by a dozen MDs and Ph.Ds out of Harvard. Elevian’s scientific founders started the company after identifying specific circulating factors that may be responsible for the “young blood” effect.
One example: A naturally occurring molecule known as “growth differentiation factor 11,” or GDF11, when injected into aged mice, reproduces many of the regenerative effects of young blood, regenerating heart, brain, muscles, lungs and kidneys.
More specifically, GDF11 supplementation reduces age-related cardiac hypertrophy, accelerates skeletal muscle repair, improves exercise capacity, improves brain function and cerebral blood flow, and improves metabolism.
Elevian is developing a number of therapeutics that regulate GDF11 and other circulating factors. The goal is to restore our body’s natural regenerative capacity, which Elevian believes can address some of the root causes of age-associated disease with the promise of reversing or preventing many aging-related diseases and extending the healthy lifespan.
In 1992, futurist Leland Kaiser coined the term “regenerative medicine”:
“A new branch of medicine will develop that attempts to change the course of chronic disease and in many instances will regenerate tired and failing organ systems."
Since then, the powerful regenerative medicine industry has grown exponentially to over $23.8 billion in 2018.
And this rapid growth is anticipated to continue, surpassing $151 billion by 2026.
A dramatic extension of the human healthspan is just over the horizon. Soon, we’ll all have the regenerative superpowers previously relegated to a handful of animals and comic books.
What new opportunities open up when anybody, anywhere, and at anytime can regenerate, replenish, and replace entire organs and metabolic systems on command?
(1) Platinum Longevity & Immunity Trip: This August 19-23, 2020 and September 16-20, 2020, I'm taking two groups of VIP entrepreneurs and investors on what I call my “Platinum Longevity & Immunity Trip” to San Francisco & San Diego.
Each trip will be a 5-Star (luxury) deep dive to meet 20+ companies and 30+ scientists/physicians and entrepreneurs who are leading the charge against age-related diseases and extending the human healthspan. We will also be visiting the top labs and scientists developing the diagnostics, anti-virals, vaccines and therapeutics fighting COVID-19.
Both trips are identical (with only 24 participants per trip). I will spend all 5-days with you as your private guide and provocateur. Through this personalized, action-packed program, my mission is to give you first-hand exposure to the major players, scientists, companies and treatments in the longevity and vitality arena. All your questions answered. Early access to cutting-edge treatments and products. And a behind-the scenes view of tomorrow’s longevity revolution.
Both trips are nearly sold out. To learn more and lock in your seat, visit our website here.
(2) Join FutureLoop: Over the past 2 years, I’ve built a machine-learning algorithm that scrapes the world’s news, science journals and social feeds every day to understand how exponential technologies are impacting specific topics & industries. It’s called FutureLoop.
Last month, I launched "FutureLoop Pandemic Special Edition," a daily comprehensive update on the impact of exponential technologies (AI, Robotics, Drones, Cellular Medicine, CRISPR, Networks & Sensors) on the COVID-19 pandemic.
If you participate, FutureLoop will update you every day on the latest breakthroughs in detection, prevention & cure of the COVID-19. This product is still in Beta, but it’s powerful, high-quality info, and it's free.
Your mindset is your most important tool during this pandemic. Making sure you are consuming the right information is critical to maintaining that mindset. FutureLoop offers "Data-Driven Optimism."
You can subscribe here. It’s free, fun + fast (20 seconds).